Defining 10-2 Visual Field Progression Criteria

Moraes, Carlos Gustavo De; Song, Christian; Liebmann, Jeffrey M.; Simonson, Joseph; Furlanetto, Rafael; Ritch, Robert

doi:10.1016/j.ophtha.2013.10.018

Cited by 37 publications

(22 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More recently, De Moraes et al showed a strong positive correlation between 10 and 2 MD slopes of the first 5 visual fields and the entire sequence of tests. They found a correlation coefficient of 0.86 at P < 0.001, confirming that the extrapolation of linear trends of MD slopes with an initial sequence of tests provides realistic estimates of rates of progression during the entire evaluation period and final MD values (De Moraes et al, 2014). …”

Section: Detection Of Visual Field Progressionmentioning

confidence: 71%

Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma

Moraes

Liebmann

Levin

2017

Progress in Retinal and Eye Research

Self Cite

141

123

View full text Add to dashboard Cite

Glaucomatous visual field progression has both personal and societal costs and therefore has a serious impact on quality of life. At the present time, intraocular pressure (IOP) is considered to be the most important modifiable risk factor for glaucoma onset and progression. Reduction of IOP has been repeatedly demonstrated to be an effective intervention across the spectrum of glaucoma, regardless of subtype or disease stage. In the setting of approval of IOP-lowering therapies, it is expected that effects on IOP will translate into benefits in long-term patient-reported outcomes. Nonetheless, the effect of these medications on IOP and their associated risks can be consistently and objectively measured. This helps to explain why regulatory approval of new therapies in glaucoma has historically used IOP as the outcome variable. Although all approved treatments for glaucoma involve IOP reduction, patients frequently continue to progress despite treatment. It would therefore be beneficial to develop treatments that preserve visual function through mechanisms other than lowering IOP. The United States Food and Drug Administration (FDA) has stated that they will accept a clinically meaningful definition of visual field progression using Glaucoma Change Probability criteria. Nonetheless, these criteria do not take into account the time (and hence, the speed) needed to reach significant change. In this paper we provide an analysis based on the existing literature to support the hypothesis that decreasing the rate of visual field progression by 30% in a trial lasting 12–18 months is clinically meaningful. We demonstrate that a 30% decrease in rate of visual field progression can be reliably projected to have a significant effect on health-related quality of life, as defined by validated instruments designed to measure that endpoint.

show abstract

Section: Detection Of Visual Field Progressionmentioning

confidence: 71%

Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma

Moraes

Liebmann

Levin

2017

Progress in Retinal and Eye Research

Self Cite

141

123

View full text Add to dashboard Cite

show abstract

“…De Moraes et al [21] recently developed and validated a set of criteria that uses PLR analysis of the threshold sensitivity data obtained with 10-2 Humphrey visual field tests to detect progression. These criteria include the slopes and statistical significance of changes in sensitivity over time.…”

Section: Assessment Of the Central Visual Field In Glaucomamentioning

confidence: 99%

“…Uniquely, an additional criterion for progression also takes into account the locations of clusters of progressing testing locations within seven possible sectors within the central 10°of the visual field. These sectors are defined based on the fact they include testing locations that are highly correlated with respect to the fact they progress at similar frequencies and rates [21].…”

Section: Assessment Of the Central Visual Field In Glaucomamentioning

confidence: 99%

Evaluation of Visual Field Progression in Glaucoma

Tanna¹,

Desai²

2014

Curr Ophthalmol Rep

View full text Add to dashboard Cite

Detection of visual field progression is of critical importance in the management of patients with glaucoma; however, there is no agreed upon set of criteria for the definition of progression. The most commonly utilized method of progression detection in clinical practice may be subjective assessment of serial visual fields. Event-based and trend-based approaches to the analysis of serial visual field data are quite powerful and used in clinical practice and in clinical research. Recent advances in analysis of visual field progression are discussed in this review article.

show abstract

“…De Moraes e colaboradores publicaram vários estudos usando a análise de tendência para detectar progressão na perimetria 24-2 e 30-2, bem como testando a relação entre as taxas de progressão, fatores de risco do glaucoma e efeitos do tratamento clínico e cirúrgico (42)(43)(44)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59) . Por exemplo, em estudo com Demirel et al (44) (43) observaram um efeito semelhante da terapia de redução da pressão intraocular na taxa de progressão medida com análise de tendência (Figura 3).…”

Section: Progressão Funcionalunclassified

“…B) Dados OHTS: comparação entre as alterações da pressão intraocular absoluta (mm Hg, abcissa) e alterações no MD do campo visual (dB/ano, eixo y), após o tratamento. A linha preta corresponde à linha de regressão linear (P <1%) e representa uma relação significativa entre a magnitude de redução da pressão intraocular e a mudança quantitativa na taxa de progressão Em relação à perimetria acromática 10-2, estudos recentes investigaram o padrão e as taxas de progressão perimétrica em bancos de dados retrospectivos (52,58,61) . Foi descrito, por exemplo, um padrão de progressão na perimetria 10-2 similar ao observado em estudos utilizando-se a perimetria 30-2 realizada há mais de 30 anos (38) .…”

Section: Progressão Funcionalunclassified

Progressão estrutural e funcional da lesão glaucomatosa na mácula

Moraes¹

View full text Add to dashboard Cite

show abstract

Defining 10-2 Visual Field Progression Criteria

Cited by 37 publications

References 44 publications

Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma

Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma

Evaluation of Visual Field Progression in Glaucoma

Progressão estrutural e funcional da lesão glaucomatosa na mácula

Contact Info

Product

Resources

About